GlassScriptPhysician profile
Teal Ann Sander
NPI 1629526926
$1,763.74
in general payments reported to CMS, 2019-2025
37 companies · $550 in 2025
The $550 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $383 · 2022: $174 · 2024: $657 · 2025: $550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,206.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $178.48 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $177.93 | 2021-2025 | |
| Abbvie INC. | $106.35 | 2021-2024 | |
| Janssen Biotech, INC. | $101.77 | 2024-2025 | Tecvayli, Darzalex, Erleada |
| Tersera Therapeutics LLC | $90.13 | 2024 | Zoladex |
| Sobi, INC | $80.36 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $63.04 | 2025 | Onivyde |
| Astrazeneca Pharmaceuticals LP | $59.10 | 2024 | Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $56.55 | 2024-2025 | Fruzaqla, Iclusig |
| Glaxosmithkline, LLC. | $56.06 | 2024-2025 | Ojjaara |
| Janssen Pharmaceuticals, INC | $52.35 | 2022 | |
| Novocure INC. | $52.04 | 2024-2025 | Optune Lua (Novottf-200t), Optune |
| Taiho Oncology, INC. | $50.16 | 2024-2025 | |
| Novo Nordisk INC | $49.40 | 2021 | |
| Amgen INC. | $43.66 | 2021 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Teal Sander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.